Utvalda publikationer ( Fredrik Piehls forskargrupp)

Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis. Starvaggi Cucuzza C, Longinetti E, Ruffin N, Evertsson B, Kockum I, Jagodic M, Al Nimer F, Frisell T, Piehl F. Neurol Neuroimmunol Neuroinflamm. 2022 Nov 21;10(1):e200056. doi: 10.1212/NXI.0000000000200056. PMID: 36411076

Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial. Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA, Håkansson I, Johansson R, Jons D, Kmezic I, Lindberg C, Lindh J, Lundin F, Nygren I, Punga AR, Press R, Samuelsson K, Sundström P, Wickberg O, Brauner S, Frisell T. JAMA Neurol. 2022 Nov 1;79(11):1105-1112. doi: 10.1001/jamaneurol.2022.2887. PMID: 36121672

Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Svenningsson A, Frisell T, Burman J, Salzer J, Fink K, Hallberg S, Hambraeus J, Axelsson M, Nimer FA, Sundström P, Gunnarsson M, Johansson R, Mellergård J, Rosenstein I, Ayad A, Sjöblom I, Risedal A, de Flon P, Gilland E, Lindeberg J, Shawket F, Piehl F, Lycke J. Lancet Neurol. 2022 Aug;21(8):693-703. doi: 10.1016/S1474-4422(22)00209-5. PMID: 35841908

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. Alping P, Burman J, Lycke J, Frisell T, Piehl F. Neurology. 2021 Mar 16;96(11):e1574-e1584. doi: 10.1212/WNL.0000000000011545. PMID: 33514645

Differential effects on blood and cerebrospinal fluid immune protein markers and kynurenine pathway metabolites from aerobic physical exercise in healthy subjects.
Isung J, Granqvist M, Trepci A, Huang J, Schwieler L, Kierkegaard M, Erhardt S, Jokinen J, Piehl F
Sci Rep 2021 Jan;11(1):1669 Isung J, Granqvist M, Trepci A, Huang J, Schwieler L, Kierkegaard M, Erhardt S, Jokinen J, Piehl F. Sci Rep. 2021 Jan 18;11(1):1669. doi: 10.1038/s41598-021-81306-4. PMID: 33462306

Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis.
Piehl F
J Intern Med 2021 Jun;289(6):771-791Piehl F. J Intern Med. 2021 Jun;289(6):771-791. doi: 10.1111/joim.13215. PMID: 33258193

Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated Fas-Casp8-Bid-axis.
Carlström KE, Zhu K, Ewing E, Krabbendam IE, Harris RA, Falcão AM, Jagodic M, Castelo-Branco G, Piehl F
Nat Commun 2020 Aug;11(1):4071 Carlström KE, Zhu K, Ewing E, Krabbendam IE, Harris RA, Falcão AM, Jagodic M, Castelo-Branco G, Piehl F. Nat Commun. 2020 Aug 13;11(1):4071. doi: 10.1038/s41467-020-17871-5. PMID: 32792491

Is the treatment of myasthenia gravis improving? Why not ask our patients?
Piehl F, Wolfe GI
Neurology 2020 Sep;95(12):509-510 Piehl F, Wolfe GI. Neurology. 2020 Sep 22;95(12):509-510. doi: 10.1212/WNL.0000000000010578. PMID: 32759197

Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.
Brauner S, Eriksson-Dufva A, Hietala MA, Frisell T, Press R, Piehl F
JAMA Neurol 2020 Aug;77(8):974-981. Brauner S, Eriksson-Dufva A, Hietala MA, Frisell T, Press R, Piehl F. JAMA Neurol. 2020 Aug 1;77(8):974-981. doi: 10.1001/jamaneurol.2020.0851. PMID: 32364568

Blood neurofilament light levels segregate treatment effects in multiple sclerosis.
Delcoigne B, Manouchehrinia A, Barro C, Benkert P, Michalak Z, Kappos L, Leppert D, Tsai JA, Plavina T, Kieseier BC, Lycke J, Alfredsson L, Kockum I, Kuhle J, Olsson T, Piehl F
Neurology 2020 Mar;94(11):e1201-e1212 Delcoigne B, Manouchehrinia A, Barro C, Benkert P, Michalak Z, Kappos L, Leppert D, Tsai JA, Plavina T, Kieseier BC, Lycke J, Alfredsson L, Kockum I, Kuhle J, Olsson T, Piehl F. Neurology. 2020 Mar 17;94(11):e1201-e1212. doi: 10.1212/WNL.0000000000009097. PMID: 32047070

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T
JAMA Neurol 2020 Feb;77(2):184-191. Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T. JAMA Neurol. 2020 Feb 1;77(2):184-191. doi: 10.1001/jamaneurol.2019.3365. PMID: 31589278

Rituximab treatment for multiple sclerosis.
Ineichen BV, Moridi T, Granberg T, Piehl F
Mult Scler 2020 Feb;26(2):137-152 Ineichen BV, Moridi T, Granberg T, Piehl F. Mult Scler. 2020 Feb;26(2):137-152. doi: 10.1177/1352458519858604. Epub 2019 Jun 25. PMID: 31237800

Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes.
Carlström KE, Ewing E, Granqvist M, Gyllenberg A, Aeinehband S, Enoksson SL, Checa A, Badam TVS, Huang J, Gomez-Cabrero D, Gustafsson M, Al Nimer F, Wheelock CE, Kockum I, Olsson T, Jagodic M, Piehl F
Nat Commun 2019 Jul;10(1):3081 Carlström KE, Ewing E, Granqvist M, Gyllenberg A, Aeinehband S, Enoksson SL, Checa A, Badam TVS, Huang J, Gomez-Cabrero D, Gustafsson M, Al Nimer F, Wheelock CE, Kockum I, Olsson T, Jagodic M, Piehl F. Nat Commun. 2019 Jul 12;10(1):3081. doi: 10.1038/s41467-019-11139-3. PMID: 31300673